PMID- 17204908
OWN - NLM
STAT- MEDLINE
DCOM- 20070618
LR  - 20181201
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 48
IP  - 6
DP  - 2006 Dec
TI  - Does the C-type natriuretic peptide have prognostic value in chagas disease and 
      other dilated cardiomyopathies?
PG  - 293-8
AB  - Atrial natriuretic peptides (ANP) and brain natriuretic peptides (BNP) are 
      powerful neurohormonal indicators of left-ventricular function and prognosis in 
      heart failure (HF). Chagas disease (CD) caused by the protozoan Trypanosoma cruzi 
      remains a major cause of HF in Latin America. We assessed whether the plasma 
      concentration of the third natriuretic peptide, C-type natriuretic peptide (CNP), 
      also has diagnostic and prognostic properties in patients with CD or other 
      dilated cardiomyopathies (DCM). Blood samples were obtained from 66 patients with 
      CD, 50 patients with DCM from other causes, and 30 gender- and age-matched 
      healthy subjects. Patients were subdivided according to the New York Heart 
      Association (NYHA) class. The CNP concentration was determined by 
      radioimmunoassay (Immundiagnostik, Bensheim, Germany). The main duration of 
      follow-up was 31.4 months (range 13 to 54 months); 19 patients had died and 11 
      patients received a heart transplant. CNP concentrations were only significantly 
      altered in patients with DCM or CD of the NYHA classes III and IV (P < 0.05). The 
      Pearson correlation of echocardiographic data with CNP revealed an association 
      only with the left-ventricular end systolic volume (P = 0.03) in patients with 
      DCM. Furthermore, CNP did not predict mortality or the necessity for heart 
      transplant. Our data are the first to demonstrate the raised levels of the third 
      natriuretic peptide CNP in CD and other DCM. Whereas ANP and BNP have a high 
      predictive value for mortality in both diseases, CNP is without any predictive 
      potency.
FAU - Heringer-Walther, Silvia
AU  - Heringer-Walther S
AD  - Department of Cardiology and Pneumology, CUM, Campus Benjamin Franklin (CBF), 
      Berlin, Germany.
FAU - Moreira, Maria da Consolacao V
AU  - Moreira Mda C
FAU - Wessel, Niels
AU  - Wessel N
FAU - Wang, Yong
AU  - Wang Y
FAU - Ventura, Tiago Moreira
AU  - Ventura TM
FAU - Schultheiss, Heinz-Peter
AU  - Schultheiss HP
FAU - Walther, Thomas
AU  - Walther T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Carbazoles)
RN  - 0 (Propanolamines)
RN  - 0K47UL67F2 (Carvedilol)
RN  - 127869-51-6 (Natriuretic Peptide, C-Type)
SB  - IM
MH  - Adult
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Antihypertensive Agents/therapeutic use
MH  - Blood Pressure/drug effects
MH  - Carbazoles/therapeutic use
MH  - Cardiomyopathy, Dilated/*blood/physiopathology/therapy
MH  - Carvedilol
MH  - Chagas Disease/*blood/physiopathology/therapy
MH  - Echocardiography
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Transplantation
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, C-Type/*blood
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Propanolamines/therapeutic use
MH  - Stroke Volume/drug effects
MH  - Survival Analysis
MH  - Ventricular Dysfunction, Left/blood/physiopathology/therapy
EDAT- 2007/01/06 09:00
MHDA- 2007/06/19 09:00
CRDT- 2007/01/06 09:00
PHST- 2007/01/06 09:00 [pubmed]
PHST- 2007/06/19 09:00 [medline]
PHST- 2007/01/06 09:00 [entrez]
AID - 00005344-200612000-00005 [pii]
AID - 10.1097/01.fjc.0000249892.22635.46 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2006 Dec;48(6):293-8. doi: 
      10.1097/01.fjc.0000249892.22635.46.